Unlabelled: We present an unusual case of ruptured sinus of Valsalva (RSOV) in the right atrium, progressive exertional dyspnea, occasional epigastric heaviness, and palpitations. The examination revealed high-pitch continuous murmur. On transthoracic echocardiography, there was a ~5-6 mm size RSOV of non-coronary sinus into right atrium, continuous turbulent flow, and unusual presentation of severe central aortic regurgitation jet with holodiastolic flow reversal seen in the descending aorta. The sinus of Valsalva aneurysm is a rare pathology, which is generally asymptomatic. In this case it manifested through a rupture into the right atrium and needed to be closed to relieve the symptoms. Transcathter closure of RSOV was done by using Amplatzer duct occluding device, there was no residual shunt, and aortic regurgitation completely disappeared.

Learning Objective: This is a unique case in which ruptured sinus of Valsalva flow and holodiastolic flow reversal were confused with severe aortic regurgitation. Careful and detailed transthoracic echocardiography played a key role in correct diagnosis and proper management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11143718PMC
http://dx.doi.org/10.1016/j.jccase.2024.02.002DOI Listing

Publication Analysis

Top Keywords

sinus valsalva
16
aortic regurgitation
16
ruptured sinus
12
severe aortic
8
case ruptured
8
transthoracic echocardiography
8
holodiastolic flow
8
flow reversal
8
sinus
5
transcatheter closure
4

Similar Publications

BACKGROUND A single coronary artery is a rare congenital anomaly of the coronary arteries distribution, with an incidence of only 0.03% in the general population undergoing coronary angiography. RCA arising from the distal circumflex artery is an extremely rare variety.

View Article and Find Full Text PDF

Trans-Coronary Sinus Intra-Septal Radiofrequency Ablation (TIRA) for Hypertrophic Obstructive Cardiomyopathy: First-in-Human Results.

Biomedicines

December 2024

Department of Internal Medicine, Pusan National University School of Medicine and Cardiology, Cardiovascular Center and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.

Background: Current treatments for hypertrophic obstructive cardiomyopathy (HOCM), including medication, surgery, and alcohol septal ablation (ASA), have limitations in terms of efficacy and safety. To address these challenges, we developed the trans-coronary intra-septal radiofrequency ablation (TIRA) device.

Methods: This first-in-human trial was conducted to assess the efficacy and safety of the TIRA device.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!